drugset / Trial / NCT06139393

Clinical Study of HR091506 Tablets in Treatment of Gout With Hyperuricemia in Adults

NCT06139393

Phase 3 Completed 765 enrolled Jiangsu HengRui Medicine Co., Ltd.
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The study is being conducted to evaluate the efficacy, and safety of HR091506 tablets for treatment of gout with hyperuricemia in adults, and to compare the results with febuxostat tablets in the same doses.

Timeline

Start
2023-12-14
Primary completion
2025-08-18
Completion
2025-09-04

Drugs

EvaluationDrugModalityDoseRoute
Comparator Febuxostat Small molecule 40 mg
Subject HR091506 Unknown 40 mg

Indications